These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
356 related articles for article (PubMed ID: 18484781)
21. Role of trastuzumab in adjuvant therapy for locally invasive breast cancer. Kabe KL; Kolesar JM Am J Health Syst Pharm; 2006 Mar; 63(6):527-33. PubMed ID: 16522889 [TBL] [Abstract][Full Text] [Related]
22. Minimizing cardiotoxicity while optimizing treatment efficacy with trastuzumab: review and expert recommendations. Martín M; Esteva FJ; Alba E; Khandheria B; Pérez-Isla L; García-Sáenz JA; Márquez A; Sengupta P; Zamorano J Oncologist; 2009 Jan; 14(1):1-11. PubMed ID: 19147689 [TBL] [Abstract][Full Text] [Related]
23. Anthracycline cardiotoxicity in breast cancer patients: synergism with trastuzumab and taxanes. Gianni L; Salvatorelli E; Minotti G Cardiovasc Toxicol; 2007; 7(2):67-71. PubMed ID: 17652806 [TBL] [Abstract][Full Text] [Related]
25. Docetaxel in the adjuvant therapy of HER-2 positive breast cancer patients. Vici P; Viola G; Botti C; Rossi S; Vitucci C; Corsetti S; Di Lauro L; Sergi D; Foggi P; Perri P; Tirelli C; Mottolese M; Fattoruso SI; Lopez M Clin Ter; 2008; 159(6):449-52. PubMed ID: 19169607 [TBL] [Abstract][Full Text] [Related]
26. Trastuzumab-induced cardiotoxicity: heart failure at the crossroads. Sengupta PP; Northfelt DW; Gentile F; Zamorano JL; Khandheria BK Mayo Clin Proc; 2008 Feb; 83(2):197-203. PubMed ID: 18241629 [TBL] [Abstract][Full Text] [Related]
27. Efficacy and cardiac safety of adjuvant trastuzumab-based chemotherapy regimens for HER2-positive early breast cancer. Costa RB; Kurra G; Greenberg L; Geyer CE Ann Oncol; 2010 Nov; 21(11):2153-2160. PubMed ID: 20351072 [TBL] [Abstract][Full Text] [Related]
29. First-line trastuzumab plus epirubicin and cyclophosphamide therapy in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer: cardiac safety and efficacy data from the Herceptin, Cyclophosphamide, and Epirubicin (HERCULES) trial. Untch M; Muscholl M; Tjulandin S; Jonat W; Meerpohl HG; Lichinitser M; Manikhas AG; Coumbos A; Kreienberg R; du Bois A; Harbeck N; Jackisch C; Müller V; Pauschinger M; Thomssen C; Lehle M; Catalani O; Lück HJ J Clin Oncol; 2010 Mar; 28(9):1473-80. PubMed ID: 20177030 [TBL] [Abstract][Full Text] [Related]
30. High-sensitivity C-reactive protein (hs-CRP) as a biomarker for trastuzumab-induced cardiotoxicity in HER2-positive early-stage breast cancer: a pilot study. Onitilo AA; Engel JM; Stankowski RV; Liang H; Berg RL; Doi SA Breast Cancer Res Treat; 2012 Jul; 134(1):291-8. PubMed ID: 22476854 [TBL] [Abstract][Full Text] [Related]
31. Cardiotoxicity and Cardiac Monitoring During Adjuvant Trastuzumab in Daily Dutch Practice: A Study of the Southeast Netherlands Breast Cancer Consortium. Seferina SC; de Boer M; Derksen MW; van den Berkmortel F; van Kampen RJ; van de Wouw AJ; Joore M; Peer PG; Voogd AC; Tjan-Heijnen VC Oncologist; 2016 May; 21(5):555-62. PubMed ID: 27009939 [TBL] [Abstract][Full Text] [Related]
32. Trastuzumab interruption and treatment-induced cardiotoxicity in early HER2-positive breast cancer. Yu AF; Yadav NU; Lung BY; Eaton AA; Thaler HT; Hudis CA; Dang CT; Steingart RM Breast Cancer Res Treat; 2015 Jan; 149(2):489-95. PubMed ID: 25552363 [TBL] [Abstract][Full Text] [Related]
33. Adjuvant trastuzumab: a milestone in the treatment of HER-2-positive early breast cancer. Baselga J; Perez EA; Pienkowski T; Bell R Oncologist; 2006; 11 Suppl 1():4-12. PubMed ID: 16971734 [TBL] [Abstract][Full Text] [Related]
34. Reversibility of trastuzumab-related cardiotoxicity: new insights based on clinical course and response to medical treatment. Ewer MS; Vooletich MT; Durand JB; Woods ML; Davis JR; Valero V; Lenihan DJ J Clin Oncol; 2005 Nov; 23(31):7820-6. PubMed ID: 16258084 [TBL] [Abstract][Full Text] [Related]
35. The role of trastuzumab in early stage breast cancer: current data and treatment recommendations. Lin A; Rugo HS Curr Treat Options Oncol; 2007 Feb; 8(1):47-60. PubMed ID: 17660958 [TBL] [Abstract][Full Text] [Related]
36. Trastuzumab-induced cardiotoxicity: a review of clinical risk factors, pharmacologic prevention, and cardiotoxicity of other HER2-directed therapies. Dempsey N; Rosenthal A; Dabas N; Kropotova Y; Lippman M; Bishopric NH Breast Cancer Res Treat; 2021 Jul; 188(1):21-36. PubMed ID: 34115243 [TBL] [Abstract][Full Text] [Related]
37. Trastuzumab-related cardiac events in the treatment of early breast cancer. Fried G; Regev T; Moskovitz M Breast Cancer Res Treat; 2013 Nov; 142(1):1-7. PubMed ID: 24154507 [TBL] [Abstract][Full Text] [Related]
38. Anthracyclines/trastuzumab: new aspects of cardiotoxicity and molecular mechanisms. Rochette L; Guenancia C; Gudjoncik A; Hachet O; Zeller M; Cottin Y; Vergely C Trends Pharmacol Sci; 2015 Jun; 36(6):326-48. PubMed ID: 25895646 [TBL] [Abstract][Full Text] [Related]
39. Monitoring the introduction of new drugs--Herceptin to cardiotoxicity. Routledge HC; Rea DW; Steeds RP Clin Med (Lond); 2006; 6(5):478-81. PubMed ID: 17080896 [TBL] [Abstract][Full Text] [Related]
40. Trastuzumab and cardiotoxicity: weighing the risks. Wong SF Am J Health Syst Pharm; 2006 Mar; 63(6):525. PubMed ID: 16522888 [No Abstract] [Full Text] [Related] [Previous] [Next] [New Search]